ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a company focused on developing oncology treatments, has shared new data on its drug candidates, ORIC-944 and ORIC-613, at the American Association for Cancer Research (AACR) Annual Meeting. These candidates aim to address specific mechanisms of therapeutic resistance in cancer.
-
ORIC-944: This PRC2 inhibitor is being developed for prostate cancer and has demonstrated preclinical efficacy when used in combination with androgen receptor (AR) inhibitors. Its properties suggest it could outperform existing PRC2 inhibitors, with a strong potency and a favorable clinical half-life of approximately 20 hours.
-
ORIC-613: This PLK4 inhibitor has shown synthetic lethality in TRIM37-high tumor models, indicating its potential as a first- and best-in-class treatment for tumors with high TRIM37 expression. Preclinical studies have shown that ORIC-613 leads to tumor regressions through potent and selective inhibition.
Both drug candidates are part of ORIC Pharmaceuticals' efforts to develop precision medicines that can overcome cancer resistance mechanisms. The company's pipeline also includes other promising treatments targeting various cancer mutations.
The data presented at the AACR Annual Meeting underscores ORIC Pharmaceuticals' commitment to advancing cancer treatment options. While the company's financial health shows a strong cash position and positive analyst revisions, it's important to note that profitability is not expected in the near term, reflecting the inherent risks of investing in the biotechnology sector.
